ethylenediamine Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Ethylenediamine is a strongly basic amine useful as a building block in chemical synthesis. It is used as a solvent to dissolve proteins such as albumins, casein and in medicine to stabilize aminophylline when used in injections. Ethylenediamine is used in manufacture of chelating agents (EDTA), epoxy curing agents, dimethylolethylene-urea resins, emulsifying agents, textile lubricants, antifreeze inhibitor. It is also involved in the manufacture of many industrial chemicals and forms derivatives with carboxylic acids, nitriles, alcohols, alkylating agents, carbon disulfide, aldehydes and ketones. It is a basic building block to prepare heterocyclic compound such as imidazolidines.   NCATS

Chemistry

  • SMILES: NCCN
  • InChIKey: PIICEJLVQHRZGT-UHFFFAOYSA-N
  • Mol. Mass: 60.0983
  • ALogP: -1.1
  • ChEMBL Molecule:
    ethylenediamine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

1,2-diaminoethane | 1,2-ethanediamine | edamine | ethane-1,2-diamine | ethyl diamine | ethylenediamine | ethylenediamine (1:1) sulfate | ethylenediamine (1:1) sulfite | ethylenediamine, 3h-labeled cpd | ethylenediamine conjugate acid | ethylenediamine dihydrobromide | ethylenediamine dihydrochloride | ethylenediamine dihydrogen iodide | ethylenediamine dihydroiodide | ethylenediamine dinitrate | ethylenediamine hydrochloride | ethylenediamine monohydrochloride | ethylenediamine phosphate | ethylenediamine sulfate

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Excipients

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Dermatitis, Allergic Contact (Phase 4)

Excipients ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue